Evidence map›Paper›PMID 37140748›Full record

ArticleAnnals of surgical oncology2023

National Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.

Lucia Calthorpe, Fernanda Romero-Hernandez, Megan Casey, Miguel Nunez, Patricia C Conroy, Kenzo Hirose, Alex Kim, Kimberly Kirkwood, Ajay V Maker, Carlos Corvera and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Lucia CalthorpeDepartment of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Fernanda Romero-HernandezDepartment of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Megan CaseySchool of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Miguel NunezSchool of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Patricia C ConroyDepartment of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Kenzo HiroseDivision of Surgical Oncology, Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Alex KimDivision of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, OH, USA.
Kimberly KirkwoodDivision of Surgical Oncology, Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Ajay V MakerDivision of Surgical Oncology, Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Carlos CorveraDivision of Surgical Oncology, Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Eric NakakuraDivision of Surgical Oncology, Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Adnan AlseidiDivision of Surgical Oncology, Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Mohamed Abdelgadir AdamDivision of Surgical Oncology, Department of Surgery, University of California, San Francisco, San Francisco, CA, USA. mohamed.adam@ucsf.edu.
University of California, San Francisco · USThe Ohio State University · US

Funding

NRSA Training CoreTL1TR001871 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KANAYA, ALKA M., SOMSOUK, MA · 2016 to 2025
$10.1M
NCATS NIH HHS TL1 TR001871
6 · The paper itself

Abstract

backgroundMalignant peritoneal mesothelioma (MPM) is a rare malignancy with a historically poor prognosis. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as an effective therapy for patients with peritoneal malignancies. A contemporary analysis of trends in management of and survival from MPM is warranted.

methodsPatients with MPM were identified from the National Cancer Database (2004-2018). Patients were categorized by treatment (CRS-HIPEC, CRS-chemotherapy, CRS only, chemotherapy only, no treatment), and joinpoint regression was employed to compute the annual percent change (APC) in treatment over time. Multivariable Cox proportional hazards models were used to analyze factors associated with survival.

resultsOf 2683 patients with MPM, 19.1% underwent CRS-HIPEC, and 21.1% received no treatment. Joinpoint regression revealed a statistically significant increase in the proportion of patients undergoing CRS-HIPEC over time (APC 3.21, p = 0.01), and a concurrent decrease in the proportion of patients who underwent no treatment (APC - 2.21, p = 0.02). Median overall survival was 19.5 months. Factors independently associated with survival included CRS-HIPEC, CRS, histology, sex, age, race, Charlson Comorbidity Index, insurance, and hospital type. Although there was a strong association between year of diagnosis and survival on univariate analysis (2016-2018 HR 0.67, p < 0.001), this association was attenuated after adjustment for treatment.

conclusionsCRS-HIPEC is increasingly employed as a treatment for MPM. In parallel, there has been a decrease in patients receiving no treatment with an increase in overall survival. These findings suggest that patients with MPM may be receiving more appropriate therapy; however, a substantial proportion of patients may remain undertreated.

Indexed as

Hyperthermia, InducedLung NeoplasmsMesotheliomaMesothelioma, MalignantPeritoneal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCytoreduction Surgical ProceduresHumansPrognosisRetrospective StudiesSurvival Rate

Identifiers

PMID37140748
OpenAlexW4368355759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.